Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Celldex Therapeutics, Inc.

Market Cap 2.58B 2.23B 2.05B 1.93B 3.63B 244B 3.66B 24.29B 9.46B 120B 9.7B 9.49B 414B P/E 2026 *
-7.59x
P/E 2027 * -7.54x
Enterprise Value 2B 1.73B 1.59B 1.49B 2.81B 189B 2.83B 18.8B 7.32B 92.66B 7.51B 7.35B 321B EV / Sales 2026 *
759x
EV / Sales 2027 * 174x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
1 day+1.89%
1 week+12.20%
Current month+4.77%
1 month+5.07%
3 months+11.10%
6 months+27.78%
Current year+21.24%
1 week 29.94
Extreme 29.94
33.56
1 month 28.38
Extreme 28.38
33.56
Current year 22.33
Extreme 22.33
35.79
1 year 19.52
Extreme 19.52
35.79
3 years 14.4
Extreme 14.4
53.18
5 years 14.4
Extreme 14.4
57.2
10 years 1.5
Extreme 1.5
75.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Date Insider Type Main position Quantity % Market Cap.
01-02Fiscal year

Chief Financial Officer

9,634 0.0145%
12-15Fiscal year

Executive/Senior Manager

38,666 0.0582%
12-04Sell

General Counsel

4,166 0.0063%
Change 5-day change 1-year change 3-year change Capi.($)
+1.89%+12.20%+64.16%-7.71% 2.54B
-0.22%-1.14%-11.88%-13.09% 43.51B
+0.76%+9.42%+303.09%+540.82% 33.29B
-4.74%-6.31%+10.75%-20.99% 29.9B
-0.47%-0.35%+3.38%+31.20% 29.34B
+0.06%+4.36%+13.31%+21.11% 25.42B
-0.02%+10.18% - - 14.36B
-0.98%-1.86%+53.43%+106.06% 13.18B
-0.29%-4.40%+3.13%+1.69% 12.72B
+1.67%+1.35%+105.56%+81.16% 12.08B
Average -0.23%+2.66%+60.55%+82.25% 21.63B
Weighted average by Cap. -0.60%+1.89%+61.95%+102.18%

Financials

2026 *2027 *
Net sales 2.63M 2.27M 2.09M 1.97M 3.7M 249M 3.73M 24.76M 9.64M 122M 9.89M 9.68M 422M 11.96M 10.32M 9.49M 8.93M 16.78M 1.13B 16.92M 112M 43.78M 554M 44.9M 43.94M 1.92B
Net income -330M -285M -262M -246M -463M -31.15B -467M -3.1B -1.21B -15.29B -1.24B -1.21B -52.89B -370M -320M -294M -277M -520M -34.96B -524M -3.48B -1.36B -17.16B -1.39B -1.36B -59.36B
Net Debt -584M -504M -463M -436M -819M -55.13B -826M -5.49B -2.14B -27.05B -2.19B -2.15B -93.59B -507M -438M -402M -379M -712M -47.88B -718M -4.77B -1.86B -23.5B -1.9B -1.86B -81.3B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
198
Date Price Change Volume
17/06/26 32.93 $ +1.89% 991,670
16/06/26 32.32 $ +0.62% 999,434
15/06/26 32.12 $ +2.72% 1,007,164
12/06/26 31.27 $ +4.37% 599,806
11/06/26 29.96 $ +2.08% 982,699
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
32.93USD
Average target price
57.53USD
Spread / Average Target
+74.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLDX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!